7th IMPACCT: RWE 2019

7th IMPACCT: RWE is organized by Hanson Wade and will be held from Sep 18 - 19, 2019 at Aloft Boston Seaport District, Boston, Massachusetts, United States of America.

Who Attends:
IMPACCT: RWE provides leading innovators and experts in the Real World Evidence space with a comprehensive, industry-focused forum dedicated to supporting and advancing the generation and utilization of RWE across drug life cycle, from clinical development to commercialization. 

IMPAACT: RWE will be bringing together 60+ senior decision makers and leaders in Real World Evidence, Clinical Development, HEOR, Market Access, Pricing and Reimbursement, Observational Research and Epidemiology.

Description:
Returning for its 7th year, IMPACCT: RWE provides top innovators and leaders in the RWE space with a comprehensive industry forum dedicated to supporting and advancing the generation and utilization of real world evidence across drug life cycle, from clinical development to commercialization.

Join your peers and leading experts in this space for a collaborative open discussion aiming to tackle key challenges to accelerate the meaningful implementation of RWE-approaches to enhance clinical RandD outcomes, drive patient-centricity, and maximize the success of launch and commercialization activities.

This collaborative discussion platform will bring together stakeholders from functions across clinical development, HEOR, regulatory and medical affairs, epidemiology and RWE, to overcome key challenges to define and implement a meaningful evidence generation plan that can effectively enhance clinical RandD, support regulatory submission and decision-making, and ultimately drive commercial success.

Real world evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real world into their development programs, drug developers are now able to drive more patient-facing outcomes, by supporting it with effective evidence-based decision-making across the product life cycle.

At a point of increasing maturity, regulatory acceptance, and growing innovation, these are exciting times for all stakeholders actively involved in the efforts to advance the effective utilization and generation of real world evidence.

Leading experts in the space will be tackling questions and sharing the latest case-studies around the use of RWE in:
Patient identification
• Clinical trial design
• Historic control arms
• Outcomes research
• Observational research
• Post-launch safety studies
• Defining medical affairs strategy
• Value generation across the product life cycle
• Regulatory decision-making
• Label extensions

Speakers: CJ Hameed, Senior Director - Global RWE Center of Excellence, Pfizer, Danny Wiederkehr, Senior Director, Global HEOR Team Lead, Pfizer, David Anstatt, Executive Director, Observational Research and Data Sciences, Bristol-Myers Squibb, Frank Zhang, VP, Head of Market Access, uniQure, Javier Jimenez, VP and Global Head of RWE and Clinical Outcomes, Sanofi, John Graham, SVP, Value, Evidence and Outcomes, GlaxoSmithKline, Judy Kando, VP, Head of Medical Affairs, Tris Pharma, Keith Friend, Global Medical Director, Cardiovascular, Bristol-Myers Squibb, Leona Bessonova, Director – HEOR, Alkermes, Marla Curran, Executive Director, Head of Biometrics and Medical Writing, Paratek Pharmaceuticals, Melvin Olson, Global Head, RWD Strategy and Innovation, Novartis, Michael Lees, Head of Value, Evidence and Portfolio Strategy, Takeda, Ravi Iyer, Director, Global HEOR, Teva Pharmaceuticals, Sandy Leonard, Former VP, Medical Evidence and Observational Research, AstraZeneca, Sebastian Schneeweiss, Professor, Harvard Medical School, Tony Hebden, VP HEOR, AbbVie

Time: 8:30 am - 3:30 pm